[Featured Stock] Cellid Rises for Second Day on US-Russia Patents for COVID-19 Vaccine Technology
Cellid has been on the rise for the second consecutive day.
As of 9:45 AM on the 24th, Cellid is trading on the KOSDAQ market at 2,750 KRW, up 465 KRW (20.35%) from the previous trading day.
The day before, Cellid announced that the registration of patents in the United States and Russia for its proprietary adenovirus vector platform technology applied to the COVID-19 vaccine ‘AdCLD-CoV19-1 OMI’ had been approved.
![[Featured Stock] Cellid Rises for Second Day on US-Russia Patents for COVID-19 Vaccine Technology](http://www.asiae.co.kr/news/img_view.htm?img=2024072208164559128_1721603806.jpg)
Cellid is a bio-venture company developing cell-based immunotherapeutic vaccines and infectious disease preventive vaccines, established in a laboratory within the College of Pharmacy at Seoul National University.
It specializes in the development of anticancer immunotherapeutic vaccines and COVID-19 preventive vaccines. Its current pipeline includes CeliVax, an anticancer immunotherapeutic vaccine platform technology, and Ad5/35, an adenovirus vector-based infectious disease preventive vaccine platform technology.
Hot Picks Today
"They Came to Spend: Chinese Tourists Swipe Over 2 Trillion Won in Korea... Where Did the Money Go?"
- While Retail Investors Flocked to Semiconductors, Investment Giants Bet 47.8 Billion Won on Overlooked Stocks
- "Stock Prices Have Risen Significantly, So Taxes Should Be Paid on Gains"…Tasks Ahead for KOSPI 10,000 [KOSPI 10,000 Era] ④
- "Stalked for Years by a Stranger"... How Can Threatened Journalists Be Protected?
- NAVER Rebounds from 190,000 Won Slump to "Targeting 450,000 Won"... Revalued Through Partnership with Nvidia [Stock of the Week]
In November 2020, Cellid completed its Vaccine & Cell Gene Therapy GMP Center. It currently possesses production capabilities necessary for clinical-stage products and for products planned for commercialization after future GMP certification.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
